Rhythm Pharmaceuticals Expects to Dose First Phase III Patients in January

The company committed $350 million to a royalty buy-down. CEO David Meeker cited $92 million in third-quarter revenue and called the U.S. launch an “excellent start.”

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.